Departement of Internal Medicine II, Rheumatology/Clinical Immunology
Würzburg, Bavaria, 97074, Germany
NCT Number: NCT05604482
Giant cell arteritis (GCA) is the most common vasculitis in the elderly. Accurate diagnosis is of utmost importance in order to then initiate the necessary immunosuppressive therapy. For large-vessel GCA (LV-GCA) involving the aorta and its branches, FDG-PET/CT is the standard in imaging for diagnosis and is recommended by the guidelines. However, this only indirectly visualizes inflammation through vessel wall uptake of glucose. A new PET tracer, 68Ga-pentixafor, is used to visualize the chemokine receptor CXCR4. This receptor is expressed by cells of the immune system. In the context of inflammatory processes, upregulation of CXCL12, the ligand of CXCR4, occurs in affected tissues. The chemotactic effect of this ligand leads to the immigration of CXCR4-positive inflammatory cells into the inflamed area, which can be visualized by PET using the CXCR4-specific tracer 68Ga-Pentixafor. The value of CXCR4-PET should therefore be tested in the context of LV-GCA. This study tests the benefit of CXCR4 in therapy-naïve patients with suspected LV-GCA. For this purpose, patients will receive a FDG-PET and a CXCR4-PET for direct comparison. This is an imaging-only study. Therapy will not be affected by the study. The study is single-arm and not blinded.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Würzburg, Bavaria, 97074, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
New imaging modality using CXCR4 for imaging in GCA
Time frame: 2 years
detection of maximum measurable tracer activity on 68Ga-Pentixafor PET/CT in the area of blood vessels after a maximum of 5 days after diagnosis or when acute inflammatory activity of GCA is detected in terms of recurrence.
Time frame: 2 years
Correlation of the measured tracer activity with clinically and laboratory-chemically available parameters that are collected in clinical routine. These include CRP, peripheral blood leukocyte count, calprotectin, serum amyloid A, haptoglobin and Lactate dehydrogenase and their respective progression.
Time frame: 2 years
Correlation of tracer uptake on imaging with CXCR4-positive peripheral blood leukocyte count.
Time frame: 2 years
Comparison with imaging findings from vasculitis MRI imaging implemented in standard clinical practice, duplex sonography (CCDS), and, if performed as part of routine clinical practice, FDG PET/CT data.
Matthias Fröhlich
Other
Detection of Disease Activity in Giant Cell Arteritis Using CXCR4-PET/CT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05000138
Arteritis, Autoimmune Diseases
Montreal, Quebec, Canada
View Trial DetailsNCT04554290
Arteritis, Autoimmune Diseases
Nancy, Lorraine, France
View Trial DetailsNCT03765424
Arteritis, Autoimmune Diseases
View Trial DetailsNCT03410290
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Aortic Arch Syndromes
Tampa, Florida, United States
View Trial Details